Retina

In the UK, real-world visual outcomes of patients receiving ranibizumab for neovascular AMD fail to match those achieved in most randomized trials. But they were delivered with substantially fewer injections and hospital visits.

A new drug, ALG-1001, that blocks the transmembrane receptors that cells use to attach to their surroundings, has the potential to treat a range of retinovascular diseases

Growing evidence for the key role played by VEGF in the normal adult eye now demands that ophthalmologists give careful consideration to the use of anti-VEGF therapies.

Americans love their cars and in many places you’re virtually stranded if you don’t drive. So does vision loss stop elderly Americans from driving?

While other pharmaceutical companies are buying into ophthalmology, Pfizer is heading for the hills

Who should receive ILUVIEN® for the treatment of chronic DME-associated vision impairment

The last decade has seen some great advances, but there's still room for improvement…

Predicting treatment outcomes manages their expectations and improves your care.

If you had VMT or MH and could avoid vitrectomy, you would. Might ocriplasmin let you?

Bayer and Regeneron have presented the phase III trial data for aflibercept treatment of myopic choroidal neovascularization